Shanghai-based 111 In., which runs an online retail drugstore and healthcare platform in China, has filed for U.S. initial public offering to raise US$200 million under the name YI, according to its prospectus.
Chinese Bio-pharmaceutical Company TOT Biopharm Raises $102M Series B Round
Suzhou-based bio-pharmaceutical company TOT Biopharm has raised US$102 million series B round led by Chinese local asset management 99Fund, according to the company’s announcement.
Qiming Venture Leads $17M Series A Round In Chinese Biotech Firm CureGenetics
Suzhou city, Jiangsu Province-based biotech firm CureGenetics Co., Ltd has raised a US$17 million series A round led by Qiming Venture Partners.
Long Hill Capital Sees Opportunities In China’s Underserved Healthcare Sector
To tackle China’s structural shortage of quality healthcare services, technology and innovation can play an important role beside regulatory reform, Jiang Xiaodong, managing partner of Chinese venture firm Long Hill Capital, told China Money Network.
Decheng Capital Leads $30M Series C Round In China’s Impact Therapeutics
Chinese investment firm Decheng Capital has led a US$30 million series C round in Nanjing-based pharmaceutical firm Impact Therapeutics.
Hillhouse Capital, Decheng Capital Lead $60M Series B Round In US DNA Sequencing Platform Developer Omniome
Hillhouse Capital and Chinese healthcare-focused investment firm Decheng Capital have led a US$60 million series B found in San Diego-based DNA sequencing platform developer Omniome, Inc.
Legend Capital Joins China Renaissance To Lead $293M Investment In Chinese Diagnostics Medical Corporation
Chinese private equity firm Legend Capital has joined China Renaissance’s healthcare fund to co-lead an investment worth nearly RMB2 billion (US$293 million) in Chinese Diagnostics Medical Corporation.
Chinese Medical Solution Provider Medlinker Raises US$147M in Series D Round
Chinese medical solution provider Medlinker has raised a RMB1 billion (US$146.8 million) series D round led by China Capital Zhongcai Fund, an industrial fund management company jointly sponsored by China Investment Securities, Zhongcai Financial Holding Investment LTD and others.
Consumer Healthcare Platform Igengmei Raises $50M Series D Round
Chinese consumer medical beauty platform Igengmei raised a US$50 million series D1 round from Xiamen-based technology company Meitu and Shenzhen-based FOFs DH Fund.
Hillhouse Capital Leads $230M Series B Preferred Stock Financing In US Biopharmaceutical Firm Gossamer Bio
Hillhouse Capital has led a US$230 million series B preferred stock financing in San Diego-based biopharmaceutical firm Gossamer Bio, according to the latter’s announcement.
CICC’s Subsidiary Leads $103M Series B In Tumor Radiotherapy Start-up Allcure Medical
China Capital Investment Group (CCIG), a subsidiary of CICC, has led a RMB700 million (US$102.67 million) series B round in Beijing Allcure Medical Technology Co. Ltd., which develops standardized tumor diagnosis and treatment centers.
Oriza Seed Venture Capital Co-leads $150M Series C Round In Biopharmaceutical Firm Ascentage Pharma
Ascentage Pharma, a Chinese clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancer and other diseases, announced that it has raised a US$150 million series C round co-led by YuanMing Prudence Fund and Oriza Seed Venture Capital, as well as new investor Teng Yue Partners.
iFlytek Expands Healthcare Investment By Leading $3.8M Pre-A Round In Smart Wearable
Chinese artificial intelligence company iFlytek has led a US$3.8 million Pre-A round in Cyrcadia Asia, that develops a smart wearable bra insert and provides accurate early breast cancer detection.
Hong Kong-based Haitong Securities Leads A Series-B Round In Boston-based Biotech Firm Orig3n
One of the largest Chinese investment banks in offshore markets, Hong Kong-based Haitong International Securities Group led a Series B financing round in Boston-based biotech research firm Orig3n, according to the latter’s statement.
iCarbonX And COFCO NHRI Enter Strategic Partnership For Blood Sugar Research
iCarbonX , a Chinese artificial intelligence-enabled health data mining start-up, has signed a strategic cooperation agreement with COFCO NHRI, the central research institute under Beijing-based agricultural conglomerate COFCO Corporation, to push for the dynamic blood sugar research and its related application development.
Matrix Partners Leads $53M Series B Round In Chinese Biopharma Firm Adlai Nortye
Hangzhou-based biopharmaceutical company Adlai Nortye Biopharma announced that it has raised a US$53 million series B round from Matrix Partners China and other investors.
Yunfeng Capital and Hybio Acquire German Pharmaceutical Firm
A consortium led by Jack Ma-backed Yunfeng Capital and Shenzhen-listed Chinese biopharmaceutical company Hybio Pharmaceutical has entered into an agreement to buy all the shares of German speciality pharmaceutical firm AMW GmbH, according to the latter’s announcement.
Chinese Oncology Firm LinkDoc Raises $151M Series D Round From CIC
China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data firm LinkDoc Technology Ltd.
Shenzhen Capital Group Leads Series B Round In Genetic Sequencing Firm HaploX
Shenzhen government-backed venture capital firm Shenzhen Capital Group Co., Ltd., has led a series B round worth of hundreds of millions of RMB in Shenzhen-based genetic sequencing company HaploX, according to Haplox’s announcement.
C-Bridge Capital Leads Series B Round In Chinese Pharmaceutical Firm Nuance Biotech
Nuance Biotech, a China-based specialty pharmaceutical company, today announced series B fundraising of US$20 million with additional capital US$15 million tied to its acquisition of new products, led by C-Bridge Capital, a private equity firm focused on Chinese healthcare market.
China Merchants Capital Invests In Chinese Chemotherapy Franchise Beijing 5 Color Technology
China Merchants Capital has invested in a series A round worth hundreds of millions of RMB in Chinese third-party chemotherapy service franchise Beijing 5 Color Technology, according to the latter’s announcement.
Chinese AI Unicorn SenseTime Leads $75M Round In Hospital Wifi Provider Helian Health
SenseTime, a Chinese artificial intelligence unicorn worth US$4.5 billion, has led a US$75 million series B round in Chinese hospital wifi provider Helian Health.
Qiming Venture Leads $37M Round In Chinese Biotech Firm Alpha Biopharma
Chinese biotech firm Alpha Biopharma Inc. announced that it has completed US$37 million of its US$65 million series A financing round led by Qiming Venture Partners.
CITIC Capital Proposes To Acquire China Biologic Products Holdings For $3.65B
A unit of Chinese investment firm CITIC Capital Holdings Ltd. has offered to buy NASDAQ-listed biotech firm China Biologic Products Holdings, Inc. for US$3.65 billion, according to a security filing by CITIC. The unit, CCRE, offered US$110 in cash for each share for the company. With 33.2 million shares outstanding, the transaction is worth around US$3.65 billion. With the Hong Kong Stock Exchange and Chinese domestic regulators implementing drastic changes to IPO policies to attract the so-called "new economy" companies …
Australian Medical Device Firm Sirtex Accepts CHD’s $1.4B Acquisition Bid
Australian medical device company Sirtex Medical Limited (ASX: SRX) announced today that its board of directors has recommended acceptance of a A$1.87 billion (US$1.4 billion) acquisition proposal by Chinese alternative asset fund manager CDH Investments.
Shunewei Capital, DCM Ventures Lead $66M Series C Round In Online Pharmacy Trading And Education Platform Yaoshibang
Yaoshibang, a Guangzhou-based online pharmacy trading and education platform, announced that it has completed a RMB420 million (US$65.7 million) series C round led by Shunwei Capital and DCM Ventures.
WuXi AppTec Leads Strategic Funding In US Healthcare AI Firm Insilico Medicine
Shanghai-based pharmaceutical and medical device firm WuXi AppTec has led a strategic funding round in Insilico Medicine, a Baltimore-based artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research.
WuXi Biologics To Invest $60M For Its First Manufacturing Facility In United States
WuXi Biologics (2269.HK), an open-access biologics technology company based in China, is to invest US$60 million and hire approximately 150 employees to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility, the firm said today in an announcement.
Hillhouse Capital Leads $35M Series B+ Round In Hangzhou Just Biotherapeutics
Beijing and Hong Kong-based investment firm Hillhouse Capital has led a US$35 million series B+ round in antibody and recombinant protein biotherapeutics firm Hangzhou Just Biotherapeutics (HJB).
Zhejiang Silk Road Joins In $100M Series B Round In British Surgical Robot Developer CMR Surgical
China’s Zhejiang Silk Road Fund has participated in a US$100 million series B round in CMR Surgical Ltd, a British company developing surgical robots.
CDH Investments, Leadyond Capital Lead $39M Series B In Drug Discovery Firm HitGen
Chinese alternative asset fund manager CDH Investments and Beijing-based Leadyond Capital have led a RMB250 million (US$39 million) series B round in Chengdu-based drug discovery firm HitGen, according to HitGen’s announcement.